Early trial data points to Eli Lilly's AJ1-11095 in myelofibrosis

Eli Lilly has unveiled early Phase 1 data for AJ1-11095, an investigational oral JAK2 inhibitor for myelofibrosis. The readout highlights spleen-volume reduction, symptom gains, and a safety profile that still needs longer follow-up.

Edited by ad hoc news Products & Consumer Desk. Reviewed before publication on 06/15/2026 at 3:30 PM ET. Details in the imprint.

Eli Lilly is using Monday's fresh clinical-news slot to showcase AJ1-11095, an investigational oral JAK2 inhibitor that is being studied in myelofibrosis and was highlighted in new Phase 1 data presented at the 2026 EHA meeting. The drug is still experimental, but the first readout gives investors and hematology watchers a concrete look at what Lilly bought when it acquired Ajax Therapeutics earlier this year. BioSpace press release

Why the first AJ1-11095 readout matters

According to Lilly, AJ1-11095 is designed as a first-in-class type II JAK2 inhibitor that binds the enzyme in its inactive conformation, a different approach from approved type I JAK2 drugs. BioPharma Dive reported that in the 12-week imaging subset, 13 of 20 patients achieved at least a 35% spleen-volume reduction, while 17 participants reached the symptom-response benchmark that trial teams often use to gauge benefit in myelofibrosis. BioPharma Dive report

The same data package described a generally manageable safety profile and said no dose-limiting toxicities were observed in the escalation phase. Clinical Trials Arena added that the company saw responses across standard efficacy endpoints, including spleen-volume reduction and symptom improvement, and that the program is now moving through expansion cohorts in second-line myelofibrosis. Clinical Trials Arena analysis

For Lilly, the value of the asset is not in today's revenue line but in the option it creates in a blood-cancer category where response depth and tolerability both matter. Shares of Eli Lilly and Co. (US5324571083) traded on the NYSE at $821.34 on 06/15/2026, after the company used the EHA stage to publicize the early AJ1-11095 results.

AJ1-11095 at a glance

• Product: AJ1-11095
• Manufacturer: Eli Lilly and Co.
• Category: New Release / Launch
• Launch date: Clinical data presented June 13, 2026
• MSRP / Price: Not disclosed; investigational drug
• Availability: Clinical trial only
• Target audience: Patients with previously treated myelofibrosis and hematology specialists
• Key differentiator / USP: Oral type II JAK2 inhibitor designed to bind the inactive conformation of JAK2

This article was a.i.-assisted and editorially reviewed. Product information without warranty; prices and availability may change at short notice. Not investment advice and not a buy or sell recommendation. Trading involves risk up to and including the total loss of invested capital.